IgA nephropathy

What is IgA nephropathy？

IgA nephropathy（IgAN）is a progressive，钢轨支撑板和i支座式配电装置和支座式配电装置。^1个Annually，around25people per million worldwide are newly diagnosed with IgAN。²

What causes IgAN？

IgAN disease is driven by four steps:^3,4

1. An abnormal form of immunoglobulin A（IgA）is produced。
2. Autoantibodies are made against this abnormal form of IgA。
3. Immune complexes containing IgA are formed。
4. These immune complexes deposit in the kidneys，triggering a series of downstream pathways，including an inflammatory response，leading to progressive kidney damage and loss of kidney function。

IgAN？

IgAN is particularly hard to diagnose.Individuals in the early stages of the disease often don’t show symptoms，resulting in many patients receiving a diagnosis afterthey have already experienced significant kidney damage。^5,6

IgAN can only be correctly diagnosed through a medical procedure called a kidney biopsy。⁷

公共签名和同步索引：^5,7

Up to 30%of people who have IgAN with persistent high er levels of protein in their urine（≥1g/day）may progress to kidney failure within10years。^8个This can lead to patients requiring regular dialysis or a kidney transplant。⁹However，diagnosing IgAN early can result in managing and potentially slowing disease progression before more kidney damage can occur。

The burden of IgAN

The daily impact of IgAN on patients extends beyond just physical symptoms.IgAN can have repercussions that also hinder their capacity to work，engage socially，and pursue activities they are passionate about。^10-15

• 29.7%of people with IgAN experience depression。¹⁰
• Patients often experience fear and anxiety of disease progression and the potential need for kidney dialysis or transplant。^10,15
• Many people with IgAN can experience unemployment and productivity loss。^11,12

介质介质保护板

Current treatment options do not target the underlying disease drivers of IgAN。^1,16

IgAN is aheterogeneous disease，which means that patients may present with a variety of clinical characteristics。^{第十七节：} 

There is a need for a tailored approach to the treatment of patients with IgAN at risk of progression to kidney failure，with effective，well-tolerated treatments that can help slowor prevent progression to kidney failure and improve quality of life。^1,4,18

The organizations and websites listed above are independently operated and not managed by Novartis.Novartis assumes no responsibility for any information they may provide。